应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01541 宜明昂科-B
未开盘 07-22 16:08:56
13.000
+0.000
0.00%
最高
13.280
最低
12.580
成交量
5.90万
今开
12.580
昨收
13.000
日振幅
5.38%
总市值
48.64亿
流通市值
29.71亿
总股本
3.74亿
成交额
76.03万
换手率
0.03%
流通股本
2.29亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
宜明昂科-B(01541)股价下跌5.24%,现价港币$12.66
阿斯达克财经 · 07-15
宜明昂科-B(01541)股价下跌5.24%,现价港币$12.66
宜明昂科-B(01541)股价下跌9.537%,现价港币$12.9
阿斯达克财经 · 07-10
宜明昂科-B(01541)股价下跌9.537%,现价港币$12.9
宜明昂科-B(01541)下跌5.75%,报13.44元/股
金融界 · 07-10
宜明昂科-B(01541)下跌5.75%,报13.44元/股
港股异动 | 宜明昂科-B(01541)盘中涨超20% IMM01与替雷利珠单抗联用临床试验完成首例给药
智通财经 · 07-09
港股异动 | 宜明昂科-B(01541)盘中涨超20% IMM01与替雷利珠单抗联用临床试验完成首例给药
宜明昂科-B(01541)上涨12.68%,报13.86元/股
金融界 · 07-08
宜明昂科-B(01541)上涨12.68%,报13.86元/股
宜明昂科-B(01541)股价显著上升12.683%,现价港币$13.86
阿斯达克财经 · 07-08
宜明昂科-B(01541)股价显著上升12.683%,现价港币$13.86
宜明昂科-B07月04日主力资金流入53万元 连续3日加仓
自选股智能写手 · 07-04
宜明昂科-B07月04日主力资金流入53万元 连续3日加仓
宜明昂科-B(01541):IMM01(替达派西普)与替雷利珠单抗联用的III期临床试验完成首例患者给药
智通财经 · 07-03
宜明昂科-B(01541):IMM01(替达派西普)与替雷利珠单抗联用的III期临床试验完成首例患者给药
宜明昂科-B(01541)下跌5.06%,报12.76元/股
金融界 · 07-03
宜明昂科-B(01541)下跌5.06%,报12.76元/股
宜明昂科-B06月27日获主力加仓304万元 环比增加546.81%
自选股智能写手 · 06-27
宜明昂科-B06月27日获主力加仓304万元 环比增加546.81%
宜明昂科-B06月25日遭主力抛售405万元 环比增加107.69%
自选股智能写手 · 06-25
宜明昂科-B06月25日遭主力抛售405万元 环比增加107.69%
宜明昂科(01541.HK)IMC-002新药临床试验获许可
阿斯达克财经 · 06-23
宜明昂科(01541.HK)IMC-002新药临床试验获许可
宜明昂科-B(01541):国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可
智通财经网 · 06-21
宜明昂科-B(01541):国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可
港股异动 | 宜明昂科-B(01541)盘中异动拉升涨近3% 子公司IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获国家药品监督管理局批准
智通财经 · 06-19
港股异动 | 宜明昂科-B(01541)盘中异动拉升涨近3% 子公司IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获国家药品监督管理局批准
宜明昂科-B06月18日遭主力抛售142万元 环比增加189.80%
自选股智能写手 · 06-18
宜明昂科-B06月18日遭主力抛售142万元 环比增加189.80%
宜明昂科-B06月07日主力资金流入166万元 连续5日加仓
自选股智能写手 · 06-07
宜明昂科-B06月07日主力资金流入166万元 连续5日加仓
港股异动 | 宜明昂科-B(01541)尾盘飙升逾17% 替达派西普治疗白血病获准进行III期临床试验
智通财经 · 06-07
港股异动 | 宜明昂科-B(01541)尾盘飙升逾17% 替达派西普治疗白血病获准进行III期临床试验
宜明昂科-B(01541)上涨5.4%,报15.22元/股
金融界 · 06-07
宜明昂科-B(01541)上涨5.4%,报15.22元/股
宜明昂科-B06月05日主力资金流入101万元 连续3日加仓
自选股智能写手 · 06-05
宜明昂科-B06月05日主力资金流入101万元 连续3日加仓
宜明昂科-B (01541):CD47靶向药物两项口头报告亮相ASCO,IMM01总体反应率杰出
智通财经 · 06-04
宜明昂科-B (01541):CD47靶向药物两项口头报告亮相ASCO,IMM01总体反应率杰出
加载更多
公司概况
公司名称:
宜明昂科-B
所属市场:
SEHK
上市日期:
--
主营业务:
宜明昂科生物医药技术(上海)股份有限公司是一家主要从事测试生物技术研发的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术,以及开发下一代肿瘤免疫疗法,免疫疗法主要专注于适应性免疫系统。该公司主要在中国国内和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":13,"timestamp":1721635736028,"preClose":13,"halted":0,"volume":59000,"delay":0,"floatShares":228550039,"shares":374157695,"eps":-1.1221484,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"07-22 16:08:56","open":12.58,"high":13.28,"low":12.58,"amount":760300,"amplitude":0.053846,"askPrice":13.1,"askSize":1400,"bidPrice":12.82,"bidSize":1600,"shortable":3,"etf":0,"ttmEps":-1.122148416119538,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"listingDate":1693843200000,"adjPreClose":13,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":0.598620129202027,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"2451665309","title":"宜明昂科-B(01541)股价下跌5.24%,现价港币$12.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2451665309","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451665309?lang=zh_cn&edition=full","pubTime":"2024-07-15 10:09","pubTimestamp":1721009340,"startTime":"0","endTime":"0","summary":"[下跌股]宜明昂科-B(01541) 股价在上午10:09比前收市价下跌5.24%,现股价为港币$12.66。至目前为止,今日最高价为$13.36,而最低价为$12.66。总成交量为2800股,总成交金额为港币$3.617万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240715442/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2450839943","title":"宜明昂科-B(01541)股价下跌9.537%,现价港币$12.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2450839943","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450839943?lang=zh_cn&edition=full","pubTime":"2024-07-10 11:57","pubTimestamp":1720583820,"startTime":"0","endTime":"0","summary":"[下跌股]宜明昂科-B(01541) 股价在上午11:57比前收市价下跌9.537%,现股价为港币$12.9。至目前为止,今日最高价为$14.76,而最低价为$12.9。总成交量为17.06万股,总成交金额为港币$233.062万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407101213/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2450288792","title":"宜明昂科-B(01541)下跌5.75%,报13.44元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450288792","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450288792?lang=zh_cn&edition=full","pubTime":"2024-07-10 10:26","pubTimestamp":1720578401,"startTime":"0","endTime":"0","summary":"7月10日,宜明昂科-B(01541)盘中下跌5.75%,截至10:26,报13.44元/股,成交141.5万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司,主要致力于开发肿瘤免疫疗法,特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉,包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报,宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/10102641477590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2450095120","title":"港股异动 | 宜明昂科-B(01541)盘中涨超20% IMM01与替雷利珠单抗联用临床试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2450095120","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450095120?lang=zh_cn&edition=full","pubTime":"2024-07-09 15:30","pubTimestamp":1720510243,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,宜明昂科-B盘中涨超20%,截至发稿,涨12.4%,报14.5港元,成交额614.65万港元。消息面上,宜明昂科发布公告,公司于2024年7月1日成功就IMM01与替雷利珠单抗联用治疗程序性细胞死亡蛋白1抑制剂治疗后复发或病情有所进展的复发性或难治性(R/R)经典霍奇金淋巴瘤患者的III期临床试验完成首例患者给药。此外,公司上月底公布,已获得中国国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1147595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1161","01541","07226","BK1576","HSCEI","YANG","HSTECH","BK1141","BK1583"],"gpt_icon":0},{"id":"2449744055","title":"宜明昂科-B(01541)上涨12.68%,报13.86元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449744055","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449744055?lang=zh_cn&edition=full","pubTime":"2024-07-08 14:51","pubTimestamp":1720421504,"startTime":"0","endTime":"0","summary":"7月8日,宜明昂科-B(01541)盘中上涨12.68%,截至14:51,报13.86元/股,成交189.88万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司,主要致力于开发肿瘤免疫疗法,特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉,包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报,宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/08145141428329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2449836742","title":"宜明昂科-B(01541)股价显著上升12.683%,现价港币$13.86","url":"https://stock-news.laohu8.com/highlight/detail?id=2449836742","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449836742?lang=zh_cn&edition=full","pubTime":"2024-07-08 14:51","pubTimestamp":1720421460,"startTime":"0","endTime":"0","summary":"[上升股]宜明昂科-B(01541) 股价在下午02:51比前收市价显著上升12.683%,现股价为港币$13.86。至目前为止,今日最高价为$13.86,而最低价为$12.12。总成交量为15.3万股,总成交金额为港币$189.601万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407081276/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2448175411","title":"宜明昂科-B07月04日主力资金流入53万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448175411","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448175411?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:15","pubTimestamp":1720080931,"startTime":"0","endTime":"0","summary":"07月04日, 宜明昂科-B股价跌1.09%,报收12.68元,成交金额159万元,换手率0.05%,振幅5.15%,量比0.62。宜明昂科-B今日主力资金净流入53万元,连续3日净流入,上一交易日主力净流入39万元,今日环比增加35.90%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为42.86%,平均涨幅为2.12%。该股近5个交易日下跌8.00%,主力资金累计净流入494万元;近20日主力资金累计净流入14万元,其中净流入天数为10日。该股主力净额占比0.02%,港股市场排名156/2644。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615599573d4a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615599573d4a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2448938172","title":"宜明昂科-B(01541):IMM01(替达派西普)与替雷利珠单抗联用的III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2448938172","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448938172?lang=zh_cn&edition=full","pubTime":"2024-07-03 17:26","pubTimestamp":1719998791,"startTime":"0","endTime":"0","summary":"凭借差异化的分子设计,IMM01表现出良好的安全性并证实其激活巨噬细胞的能力。集团拥有IMM01的全球自主知识产权及商业化权利。截至本公告日期,就IMM01而言,集团拥有一个专利家族,其中包括在中国、美国、日本及欧盟的已授权专利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703173004956ce87e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703173004956ce87e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1141","01541","03347","BK1576"],"gpt_icon":0},{"id":"2448441125","title":"宜明昂科-B(01541)下跌5.06%,报12.76元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448441125","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448441125?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:36","pubTimestamp":1719984989,"startTime":"0","endTime":"0","summary":"7月3日,宜明昂科-B(01541)盘中下跌5.06%,截至13:36,报12.76元/股,成交174.25万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司,主要致力于开发肿瘤免疫疗法,特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉,包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报,宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/03133641343856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2446258818","title":"宜明昂科-B06月27日获主力加仓304万元 环比增加546.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446258818","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446258818?lang=zh_cn&edition=full","pubTime":"2024-06-27 16:16","pubTimestamp":1719476208,"startTime":"0","endTime":"0","summary":"06月27日, 宜明昂科-B股价跌1.00%,报收13.86元,成交金额392万元,换手率0.12%,振幅4.00%,量比0.86。宜明昂科-B今日主力资金净流入304万元,上一交易日主力净流入47万元,今日环比增加546.81%。该股近5个交易日下跌0.86%,主力资金累计净流出10万元;近20日主力资金累计净流出35万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271617169f6b1507&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271617169f6b1507&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2446899882","title":"宜明昂科-B06月25日遭主力抛售405万元 环比增加107.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446899882","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446899882?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:16","pubTimestamp":1719303379,"startTime":"0","endTime":"0","summary":"06月25日,宜明昂科-B股价收平报14.00元,成交金额611万元,换手率0.19%,振幅2.71%,量比2.34。宜明昂科-B今日主力资金净流出405万元,上一交易日主力净流出195万元,今日环比增加107.69%。该股近5个交易日上涨0.85%,主力资金累计净流出613万元;近20日主力资金累计净流出387万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062516164595d5ba9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062516164595d5ba9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2445218030","title":"宜明昂科(01541.HK)IMC-002新药临床试验获许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2445218030","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445218030?lang=zh_cn&edition=full","pubTime":"2024-06-23 19:21","pubTimestamp":1719141660,"startTime":"0","endTime":"0","summary":"宜明昂科-B(01541.HK) 公布,已获得中国国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可。IMC-002由集团独立研发,是一种靶向分化簇47及分化簇20的双特异性分子,通过增强的抗体依赖的细胞吞噬作用和抗体依赖的细胞毒性作用,可同时与恶性B细胞上表达的CD47和CD20结合。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1358363/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1576","BK1161","01541","03347","BK1141"],"gpt_icon":0},{"id":"2445737106","title":"宜明昂科-B(01541):国家药监局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2445737106","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445737106?lang=zh_cn&edition=full","pubTime":"2024-06-21 18:33","pubTimestamp":1718966011,"startTime":"0","endTime":"0","summary":"智通财经APP讯,宜明昂科-B 发布公告,集团已获得中国国家药品监督管理局批准进行IMC-002治疗视神经脊髓炎谱系疾病的Ib/III期临床试验的新药临床试验许可。由集团独立研发的IMC-002是一种靶向分化簇47 及分化簇20 的双特异性分子。集团拥有IMC-002的全球知识产权及商业化权利。此外,集团已获得国家药监局的IND批准,可进行IMC-002针对系统性红斑狼疮的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4134","III","BK1583","01541","03347","BK1141","BK1161","BK1576"],"gpt_icon":0},{"id":"2444427388","title":"港股异动 | 宜明昂科-B(01541)盘中异动拉升涨近3% 子公司IMC-002针对系统性红斑狼疮(SLE)的临床研究申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2444427388","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444427388?lang=zh_cn&edition=full","pubTime":"2024-06-19 18:56","pubTimestamp":1718794561,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,宜明昂科-B盘中异动拉升涨近3%,截至收盘涨0.71%,报14.26港元。据悉,相对于CD20单抗药物,CD47xCD20双靶点药物IMC-002针对SLE病人外周血B细胞具有更强的清除作用。另外有文献报道,体内敲除CD47可显著降低狼疮肾炎模型动物蛋白尿水平,同时显著延长疾病动物的寿命,因此公司相信IMC-002对中重度SLE预期会有很好的临床疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1137502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","SLE","BK1161","HSTECH","HSCEI","07226","BK4077","YANG"],"gpt_icon":0},{"id":"2444910801","title":"宜明昂科-B06月18日遭主力抛售142万元 环比增加189.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444910801","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444910801?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:16","pubTimestamp":1718698595,"startTime":"0","endTime":"0","summary":"06月18日, 宜明昂科-B股价跌0.98%,报收14.16元,成交金额217万元,换手率0.07%,振幅1.82%,量比1.20。宜明昂科-B今日主力资金净流出142万元,连续4日净流出,上一交易日主力净流出49万元,今日环比增加189.80%。该股近5个交易日下跌4.33%,主力资金累计净流出263万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入280万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181616589f499f28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181616589f499f28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2441616039","title":"宜明昂科-B06月07日主力资金流入166万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2441616039","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441616039?lang=zh_cn&edition=full","pubTime":"2024-06-07 16:15","pubTimestamp":1717748114,"startTime":"0","endTime":"0","summary":"06月07日, 宜明昂科-B股价涨7.20%,报收15.48元,成交金额697万元,换手率0.20%,振幅19.25%,量比3.21。宜明昂科-B今日主力资金净流入166万元,连续5日净流入,上一交易日主力净流入109万元,今日环比增加52.29%。该股近5个交易日上涨7.22%,主力资金累计净流入518万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入315万元,其中净流入天数为7日。该股主力净额占比0.05%,港股市场排名92/2630。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071615309f238640&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071615309f238640&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2441035910","title":"港股异动 | 宜明昂科-B(01541)尾盘飙升逾17% 替达派西普治疗白血病获准进行III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2441035910","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441035910?lang=zh_cn&edition=full","pubTime":"2024-06-07 15:44","pubTimestamp":1717746277,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,宜明昂科-B(01541)尾盘飙升逾17%,截至发稿,涨11.5%,报16.1港元,成交额496.77万港元。消息面上,宜明昂科近期公布,获中国国家药品监督管理局药品审评中心批准进行其核心产品IMM01(替达派西普)联合阿扎胞苷III期临床试验方案,用于慢性粒-单核细胞白血病(CMML)的一线治疗。据悉,该款产品是中国首个进入临床阶段的SIRPα-Fc融合蛋白。此外,宜明昂科近日在2024美国临床肿瘤学会(ASCO)年会上围绕核心产品替达派西普 (Timdarpacept, 项目编号: IMM01) 的两个II期临床数据发表了口头报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1132648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07226","03347","HSTECH","BK4134","YANG","HSCEI","BK1141","01541","BK1161","III","BK1583","BK1576"],"gpt_icon":0},{"id":"2441035582","title":"宜明昂科-B(01541)上涨5.4%,报15.22元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2441035582","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441035582?lang=zh_cn&edition=full","pubTime":"2024-06-07 15:39","pubTimestamp":1717745963,"startTime":"0","endTime":"0","summary":"6月7日,宜明昂科-B(01541)盘中上涨5.4%,截至15:39,报15.22元/股,成交359.48万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司,主要致力于开发肿瘤免疫疗法,特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉,包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报,宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/07153940947805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2441241992","title":"宜明昂科-B06月05日主力资金流入101万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2441241992","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441241992?lang=zh_cn&edition=full","pubTime":"2024-06-05 16:16","pubTimestamp":1717575386,"startTime":"0","endTime":"0","summary":"06月05日, 宜明昂科-B股价涨0.14%,报收14.66元,成交金额216万元,换手率0.07%,振幅3.14%,量比1.37。宜明昂科-B今日主力资金净流入101万元,连续3日净流入,上一交易日主力净流入104万元,今日环比减少2.88%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为33.33%,平均涨幅为1.85%。该股近5个交易日上涨1.24%,主力资金累计净流入242万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出45万元,其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406051616539f1c0f26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406051616539f1c0f26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2440734014","title":"宜明昂科-B (01541):CD47靶向药物两项口头报告亮相ASCO,IMM01总体反应率杰出","url":"https://stock-news.laohu8.com/highlight/detail?id=2440734014","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440734014?lang=zh_cn&edition=full","pubTime":"2024-06-04 12:38","pubTimestamp":1717475914,"startTime":"0","endTime":"0","summary":"智通财经APP了解到,宜明昂科-B 近日在2024美国临床肿瘤学会年会上围绕核心产品替达派西普 的两个II期临床数据发表了口头报告。无患者因TRAE导致永久停用研究药物或死亡。在CD47靶向药物的研发之路上,多家跨国药企先后折戟。此次ASCO年会上,宜明昂科两项II期数据成功入选口头报告,在会议现场也受到热烈的关注,表明行业权威对该项目临床数据的高度认可,以及对CD47靶向药物的研发前景的巨大期待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":-0.1022},{"period":"3month","weight":-0.0922},{"period":"6month","weight":-0.5066},{"period":"1year","weight":-0.3011},{"period":"ytd","weight":-0.5652}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术(上海)股份有限公司是一家主要从事测试生物技术研发的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术,以及开发下一代肿瘤免疫疗法,免疫疗法主要专注于适应性免疫系统。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}